Short answer · Medically reviewed summary · Last updated: 2026-04-07
The primary goal of Bronchiectasis treatment is to manage symptoms, reduce the frequency of pulmonary exacerbations, and prevent further lung damage through a combination of airway clearance techniques and targeted pharmacological therapies. Standard Medical Management First-line management for Bronchiectasis focuses on clearing excess mucus and controlling infections. Physicians typically prescribe inhaled bronchodilators (e.g., salbutamol or formoterol) to keep airways open and, in some cases, long-term macrolide antibiotics (such as azithromycin) to reduce inflammation and infection frequency.
8 people with Bronchiectasis have shared their first-person experience on this question at DiseaseMaps.
The primary goal of Bronchiectasis treatment is to manage symptoms, reduce the frequency of pulmonary exacerbations, and prevent further lung damage through a combination of airway clearance techniques and targeted pharmacological therapies.
First-line management for Bronchiectasis focuses on clearing excess mucus and controlling infections. Physicians typically prescribe inhaled bronchodilators (e.g., salbutamol or formoterol) to keep airways open and, in some cases, long-term macrolide antibiotics (such as azithromycin) to reduce inflammation and infection frequency. When patients experience acute flares, targeted antibiotic therapy is essential to address specific pathogens identified through sputum cultures.
Physical therapy is the cornerstone of Bronchiectasis care. Techniques such as the active cycle of breathing, positive expiratory pressure (PEP) devices, and postural drainage are vital for mobilizing secretions. Pulmonary rehabilitation programs are highly encouraged to improve exercise tolerance and quality of life. In rare, localized cases where symptoms remain uncontrolled despite optimal medical management, surgical resection may be considered by a thoracic surgeon.
The landscape for Bronchiectasis is evolving, with current clinical trials investigating novel mucoactive agents and inhaled dry-powder antibiotics designed to reduce the bacterial burden without systemic side effects. It is important to note that treatment effectiveness varies significantly between patients, as the underlying cause—whether it be post-infectious, genetic (like Primary Ciliary Dyskinesia), or immune-mediated—greatly dictates the optimal strategy.
Managing Bronchiectasis requires a multidisciplinary team. Your core team should include a pulmonologist, a dedicated respiratory therapist, and often an infectious disease specialist. Depending on the etiology, you may also benefit from consultations with a clinical geneticist or an immunologist to ensure your care is fully personalized to your specific medical history.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Treatment plans must be developed in consultation with your own medical team, as specific dosages and interventions depend on your unique clinical presentation.